Last reviewed · How we verify

Dinoprostone vaginal insert

HaEmek Medical Center, Israel · FDA-approved active Small molecule

Dinoprostone is a prostaglandin E2 analog that binds to prostaglandin receptors to stimulate uterine contractions and promote cervical ripening and labor induction.

Dinoprostone is a prostaglandin E2 analog that binds to prostaglandin receptors to stimulate uterine contractions and promote cervical ripening and labor induction. Used for Cervical ripening and labor induction in pregnant women at or near term.

At a glance

Generic nameDinoprostone vaginal insert
Also known asPropess
SponsorHaEmek Medical Center, Israel
Drug classProstaglandin E2 analog
TargetProstaglandin E receptors (EP1, EP3)
ModalitySmall molecule
Therapeutic areaObstetrics
PhaseFDA-approved

Mechanism of action

Dinoprostone acts as a direct agonist of prostaglandin E (EP) receptors, particularly EP1 and EP3 receptors on uterine smooth muscle and cervical tissue. This binding triggers increased intracellular calcium and myometrial contractions while simultaneously softening and dilating the cervix. The vaginal insert formulation provides sustained local delivery of the prostaglandin to facilitate labor induction in pregnant women.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: